“So we're assuming basically the same market conditions, not just China, but for the rest of the world, as well as we saw in Q2 for the remainder of the year.”

In context

“solid quarter of growth. So hopefully, that gives you some context of where things are, but we're going to keep studying it and make sure we got a good handle on our performance. And when we end ‘23, that we will be proud that we navigated the environment extremely well, deliver differentiated performance and set the company up for long-term success. Vijay Kumar: That's extremely helpful color, Marc. And maybe one follow-up here. The updated guidance, is it assuming China to remain decline for the rest of the year? And what was PPI's growth in the quarter? Stephen Williamson: So Vijay, the decline will lessen on a reported basis because of the run-up in testing factor therapy is a little bit there in terms of the support of the pandemic that we did in the back half of the year last year. So we're assuming basically the same market conditions, not just China, but for the rest of the world, as well as we saw in Q2 for the remainder of the year. Marc Casper: Clinical research, double-digit growth. Thank you, Vijay. Vijay Kumar: Fantastic. Thank you, guys. Marc Casper: Thanks. Operator: Thank you. Our next question comes from Dan Brennan from TD Cowen. Dan, your line is now open. Please proceed with your question. Dan Brennan: Great. Thanks, guys. Marc, Jets are hoping out and Rogers can navigate through a difficult schedule, certainly hope and expect you'll navigate Thermo through these more difficult macro times here. Maybe just the first one, would love to get more color on China. Could you just walk us through just more color across your major customer segments, kind of unpack, kind of how the quarter played out from that perspective? And then specifically, I would also love to hear color on bioproduction in China. Marc Casper”